Similar articles

• Bortezomib plus melphalan and prednisone for multiple myeloma.

  Avvisati G. Avvisati G. N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. N Engl J Med. 2008. PMID: 19090032 No abstract available.
• Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

  Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Palumbo A, et al. J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12. J Clin Oncol. 2010. PMID: 20940200 Clinical Trial.
• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

  Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5. Haematologica. 2008. PMID: 18322252 Clinical Trial.
• [Therapy of multiple myeloma: indications and options].

  Peest D, Ganser A. Peest D, et al. Internist (Berl). 2007 Dec;48(12):1343-8. doi: 10.1007/s00108-007-1959-x. Internist (Berl). 2007. PMID: 17960351 Review. German.
• Bortezomib in the front-line treatment of multiple myeloma.

  Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Richardson PG, et al. Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Expert Rev Anticancer Ther. 2008. PMID: 18588451 Review.